Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Vestar & Fujisawa dissolve anti-fungal development JV

Executive Summary

Vestar (pharmaceuticals to treat cancer and AIDS) and Fujisawa USA have agreed to dissolve their joint venture to develop and commercialize AmBisome, Vestar's injectable liposomal amphotericin B, an anti-fungal agent. (See new deal, April 1995.)
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Liposomes
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Joint Venture

Related Companies

UsernamePublicRestriction

Register